LENZ Therapeutics (LENZ) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

LENZ Therapeutics (LENZ) overview

LENZ Therapeutics (LENZ) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 19.1m and operating profit of USD -91.1m; the year-end share price was 16.00 USD and market capitalisation was USD 502m. LENZ Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get LENZ Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 284mFY 2025
Share price16.00 USDFY 2025 year end
RevenueUSD 19.1mFY 2025
Operating profitUSD -91.1mFY 2025
Net earningsUSD -82.1mFY 2025
Market capitalisationUSD 502mFY 2025 year end

About LENZ Therapeutics

LENZ Therapeutics is a commercial pharmaceutical company developing and commercializing therapies intended to improve vision. Its product VIZZ is a prescription eye drop for treating presbyopia, marketed in the United States through eye care professional sales, an e-pharmacy partner, and retail pharmacies. The company also pursues international licensing and distribution partnerships for VIZZ.

Generate the LENZ Therapeutics report

LENZ Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for LENZ Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on LENZ Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.